Actively Recruiting
Study of Repeated Endobiliary Radiofrequency Ablation with Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma International Randomized Controlled Trial Evaluating Survival Benefits
Led by Aichi Medical University · Updated on 2026-01-13
120
Participants Needed
8
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with unresectable extrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be surgically removed. The trial evaluates whether repeated endobiliary radiofrequency ablation EB-RFA combined with first-line systemic therapy using durvalumab, gemcitabine, and cisplatin improves overall survival compared to standard plastic stenting alone. This international, open-label, randomized controlled trial addresses the limited survival benefits of current treatments and explores local tumor control through EB-RFA. Participants are randomly assigned to one of two groups one group receives EB-RFA followed by placement of a plastic biliary stent during an initial endoscopy, with a second endoscopy at three months to repeat EB-RFA and stent exchange additional EB-RFA sessions every two months may occur if needed. The other group receives standard plastic stenting without EB-RFA, with scheduled stent exchanges at three months and thereafter as needed. All participants undergo systemic therapy with durvalumab, gemcitabine, and cisplatin throughout the study. During the study, participants undergo scheduled endoscopic procedures and systemic therapy, with researchers monitoring overall survival up to 36 months after enrollment. Secondary measures include time to recurrent biliary obstruction, progression-free survival, adverse events, and success rates of the procedures. The study includes safety monitoring and assessment of repeated biliary interventions and their impact on participants health and treatment outcomes.
CONDITIONS
Brief Title
Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma
Research Team
T
Tadahisa Inoue
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here